lung cancer research paper thesis

Lung Cancer Research Results and Study Updates

See Advances in Lung Cancer Research for an overview of recent findings and progress, plus ongoing projects supported by NCI.

In the ADAURA clinical trial, people with early-stage lung cancer treated with osimertinib (Tagrisso) after surgery lived longer than people treated with a placebo after surgery. Despite some criticisms about its design, the trial is expected to change patient care.

For certain people with early-stage non-small cell lung cancer, sublobar surgery to remove only a piece of the affected lung lobe is as effective as surgery to remove the whole lobe, new research shows.

Pragmatica-Lung is a clinical trial for people with non-small cell lung cancer that has spread beyond the lungs (stage 4 cancer). The trial will help confirm if the combination of pembrolizumab and ramucirumab helps people with advanced lung cancer live longer.

On August 11, the Food and Drug Administration (FDA) gave accelerated approval to trastuzumab deruxtecan (Enhertu) for adults with non-small cell lung cancer (NSCLC) that has a specific mutation in the HER2 gene. Around 3% of people with NSCLC have this kind of HER2 mutation.

Giving people with early-stage lung cancer the immunotherapy drug nivolumab (Opdivo) and chemotherapy before surgery can substantially delay the progression or return of their cancer, a large clinical trial found.

Atezolizumab (Tecentriq) is now the first immunotherapy approved by FDA for use as an additional, or adjuvant, treatment for some patients with non-small cell lung cancer. The approval was based on results of a clinical trial called IMpower010.

Quitting smoking after a diagnosis of early-stage lung cancer may help people live longer, a new study finds. The study, which included more than 500 patients, also found that quitting smoking delayed the cancer from returning or getting worse.

NCI scientists and their international collaborators have found that the majority of lung cancers in never smokers arise when mutations caused by natural processes in the body accumulate. They also identified three subtypes of lung cancer these individuals.

FDA has approved the first KRAS-blocking drug, sotorasib (Lumakras). The approval, which covers the use of sotorasib to treat some patients with advanced lung cancer, sets the stage for other KRAS inhibitors already in development, researchers said.

Combining the chemotherapy drug topotecan and the investigational drug berzosertib shrank tumors in some patients with small cell lung cancer, results from an NCI-supported phase 1 clinical trial show. Two phase 2 trials of the combination are planned.

Mortality rates from the most common lung cancer, non-small cell lung cancer (NSCLC), have fallen sharply in the United States in recent years, due primarily to recent advances in treatment, an NCI study shows.

In a study of more than 50,000 veterans with lung cancer, those with mental illness who received mental health treatment—including for substance use—lived substantially longer than those who didn’t participate in such programs.

FDA has granted accelerated approval for selpercatinib (Retevmo) to treat certain patients with thyroid cancer or non-small cell lung cancer whose tumors have RET gene alterations. The drug, which works by blocking the activity of RET proteins, was approved based on the results of the LIBRETTO-001 trial.

Osimertinib (Tagrisso) improves survival in people with non-small cell lung cancer with EGFR mutations, updated clinical trial results show. People treated with osimertinib lived longer than those treated with earlier-generation EGFR-targeted drugs.

A large clinical trial showed that adding the immunotherapy drug durvalumab (Imfinzi) to standard chemotherapy can prolong survival in some people with previously untreated advanced small cell lung cancer.

The investigational drug selpercatinib may benefit patients with lung cancer whose tumors have alterations in the RET gene, including fusions with other genes, according to results from a small clinical trial.

FDA has approved entrectinib (Rozlytrek) for the treatment of children and adults with tumors bearing an NTRK gene fusion. The approval also covers adults with non-small cell lung cancer harboring a ROS1 gene fusion.

Clinical recommendations on who should be screened for lung cancer may need to be reviewed when it comes to African Americans who smoke, findings from a new study suggest.

Use of a multipronged approach within hospitals, including community centers, not only eliminated treatment disparities among black and white patients with early-stage lung cancer, it also improved treatment rates for all patients, results from a new study show.

In everyday medical care, there may be more complications from invasive diagnostic procedures performed after lung cancer screening than has been reported in large studies.

The Lung Cancer Master Protocol, or Lung-MAP, is a precision medicine research study for people with advanced non-small cell lung cancer that has continued to grow after treatment. Patients are assigned to different study drug combinations based on the results of genomic profiling of their tumors.

On December 6, 2018, the Food and Drug Administration (FDA) approved atezolizumab (Tecentriq) in combination with a standard three-drug regimen as an initial treatment for advanced lung cancer that does not have EGFR or ALK mutations.

A new study has identified a potential biomarker of early-stage non–small cell lung cancer (NSCLC). The biomarker, the study’s leaders said, could help diagnose precancerous lung growths and early-stage lung cancers noninvasively and distinguish them from noncancerous growths.

Results from two large clinical trials should cement the value of the drugs brigatinib (Alunbrig) and durvalumab (Imfinzi) in treating non-small cell lung cancer (NSCLC). The trial results, several experts said, confirm that the drugs can improve the outcomes of patients with advanced NSCLC.

Cancer researchers have trained a computer program to scan images of tissue samples to differentiate normal lung tissue from the two most common forms of lung cancer. The program also learned to detect cancer-related genetic mutations in the samples.

In a large clinical trial, the immunotherapy drug atezolizumab (Tecentriq), combined with a standard chemotherapy regimen, modestly increased survival in patients with advanced small cell lung cancer (SCLC). The trial is the first in more than 20 years to show a survival improvement in this cancer.

Results from a large clinical trial show combining an immune checkpoint inhibitor with chemotherapy helped some patients with advanced lung cancer live longer than chemotherapy alone. How will this change the lung cancer treatment landscape?

An analysis of data from a demonstration project led by the Veterans Health Administration may help to better define who is most likely to benefit from lung cancer screening.

Patterns of gene expression may be different in the tumors of some African Americans than in those of whites, a new study has found, and these biological differences may contribute to racial disparities in lung cancer.

FDA has approved alectinib (Alecensa) as a first-line treatment option for patients with advanced non-small cell lung cancer that is ALK positive. Alectinib is the third ALK inhibitor to be approved in this setting.

A collection of material about the ALCHEMIST lung cancer trials that will examine tumor tissue from patients with certain types of early-stage, completely resected non-small cell lung cancer for gene mutations in the EGFR and ALK genes, and assign patients with these gene mutations to treatment trials testing post-surgical use of drugs targeted against these mutations.

FDA approved the combination of dabrafenib (Tafinlar®) and trametinib (Mekinist®) for the treatment of metastatic non-small cell lung cancer (NSCLC) that has an alteration in the BRAF gene called the V600E mutation.

The FDA has approved the targeted therapy ceritinib as an initial treatment for patients with lung cancer that has a mutation in the ALK gene.

FDA approved the immune checkpoint inhibitor pembrolizumab to be used with chemotherapy as a first-line treatment for non-small cell lung cancer.

On April 28, the FDA granted accelerated approval to the targeted therapy brigatinib (Alunbrig™) for patients with metastatic non-small cell lung cancer (NSCLC) and alterations in the ALK gene whose cancer has progressed during their initial therapy.

A demonstration project by the Veterans Health Administration is highlighting some of the complexities and challenges associated with the expansion of lung cancer screening in the United States.

Results from a phase III trial showed that the immune checkpoint inhibitor pembrolizumab (Keytruda®) improved progression-free and overall survival among patients with advanced non-small cell lung cancer compared with chemotherapy.

loading page

• Download ZIP
• Download LaTeX
• Download JATS XML
• Track citations
• Fork (make a copy)

Corresponding Author:[email protected]

Do a more advanced search »

Search for dissertations about: "lung cancer"

Showing result 1 - 5 of 329 swedish dissertations containing the words lung cancer .

1. Lung Cancer : Epidemiological and Clinical Studies with Special Reference to Surgical Treatment

Author : Gunnar Myrdal ; Elisabeth Ståhle ; Mats Lambe ; Bengt Bergman ; Uppsala universitet ; [] Keywords : MEDICAL AND HEALTH SCIENCES ; MEDICIN OCH HÄLSOVETENSKAP ; MEDICIN OCH HÄLSOVETENSKAP ; MEDICAL AND HEALTH SCIENCES ; Surgery ; lung cancer ; surgical treatment ; early mortality ; survival ; smoking ; quality of life ; adenocarcinoma ; incidence ; Sweden ; Kirurgi ; Surgery ; Kirurgi ; Thoracic and Cardivascular Suregery ; kirurgi ; särskilt thoraxkirurgi ;

Abstract : From being a rare disease in the early 1900s, lung cancer is today the most common forms of cancer worldwide. This development is due to the gradual uptake of cigarette smoking in different populations and birth cohorts during the past 75 years. READ MORE

2. Lung cancer in males : an epidemiological study in northern Sweden with special regard to smoking and occupation

Author : Lena Damber ; Umeå universitet ; [] Keywords : MEDICAL AND HEALTH SCIENCES ; MEDICIN OCH HÄLSOVETENSKAP ; MEDICIN OCH HÄLSOVETENSKAP ; MEDICAL AND HEALTH SCIENCES ; case-control study ; epidemiology ; lung cancer ; occupational risk ; factors ; smoking ; radon ; cell types ; validity ;

Abstract : In a case-control study comprising 589 cases of male lung cancer in northern Sweden longitudinal data concerning occupations, employments and smoking habits were collected by questionnaires.Pipe smoking was as common as cigarette smoking and gave very similar relative risk. READ MORE

3. LRIG1 in lung cancer : prognostic effects and mechanistic studies

Author : Samuel Kvarnbrink ; Mikael Johansson ; Håkan Hedman ; Odd Terje Brustugun ; Umeå universitet ; [] Keywords : MEDICAL AND HEALTH SCIENCES ; MEDICIN OCH HÄLSOVETENSKAP ; MEDICIN OCH HÄLSOVETENSKAP ; MEDICAL AND HEALTH SCIENCES ; lung cancer ; metastasis ; prognosis ; LRIG1 ; LRIG3 ; LMO7 ; LIMCH1 ; Oncology ; onkologi ;

Abstract : Lung cancer is the leading cause of cancer-related death worldwide as well as in Sweden. Non-small cell lung cancer (NSCLC) is the predominant form, which is largely subdivided into adenocarcinomas and squamous cell carcinomas. READ MORE

4. Cancer and Inflammation : Role of Macrophages and Monocytes

Author : Alexander Hedbrant ; Jonny Wijkander ; Dick Delbro ; Ann Erlandsson ; Anita Sjölander ; Karlstads universitet ; [] Keywords : NATURAL SCIENCES ; NATURVETENSKAP ; MEDICAL AND HEALTH SCIENCES ; MEDICIN OCH HÄLSOVETENSKAP ; MEDICAL AND HEALTH SCIENCES ; MEDICIN OCH HÄLSOVETENSKAP ; NATURVETENSKAP ; MEDICIN OCH HÄLSOVETENSKAP ; MEDICIN OCH HÄLSOVETENSKAP ; NATURAL SCIENCES ; MEDICAL AND HEALTH SCIENCES ; MEDICAL AND HEALTH SCIENCES ; M1 macrophages ; M2 macrophages ; colon cancer ; lung cancer ; prostaglandin E2 ; Biomedical Sciences ; Biomedicinsk vetenskap ;

Abstract : Macrophages are cells of the innate immune system that can be found in large quantities in cancer tumors and affect cancer progression by regulating growth and invasiveness of cancer cells. There are two main phenotypes of macrophages denoted M1 and M2. READ MORE

5. Body Protein and its Change in Patients During Anti-Tumor Treatment

Author : Lianna Kadar ; Malmö Institutionen för kliniska vetenskaper ; [] Keywords : MEDICIN OCH HÄLSOVETENSKAP ; MEDICAL AND HEALTH SCIENCES ; MEDICIN OCH HÄLSOVETENSKAP ; MEDICAL AND HEALTH SCIENCES ; Cytology ; Gastrointestinal tumors ; Breast cancer ; Lung cancer ; Prognosis ; Body protein ; oncology ; cancerology ; Cytologi ; onkologi ; cancer ;

Abstract : The purpose of this study was to investigate how total body protein and its fraction of body weight (body protein fraction) change in cancer patients during different anti-tumor treatments, and to see if these changes have any clinical significance in the form of prognostic value or correlation with disease course and tumor response. In 84 patients, 28 with lung cancer, 24 with gastrointestinal tumors, 30 with breast cancer, 1 with non-Hodgkin lymphoma and 1 with kidney cancer, the total amount of body nitrogen was measured using an in vivo prompt gamma neutron activation technique. READ MORE

Searchphrases right now

• Complexity Index
• laboratory evaluation
• gothenburg university
• Social model
• socioeconomic development
• English language theses
• uncertainty assessment
• community health

Popular searches

• Complex dynamics
• Jan Petzäll
• User Modelling
• Shell theory.
• Capital Asset Pricing Model
• Magnetic Flux Compression
• fatty acids.
• Elena Raviola
• high voltage
• culture studies
• Statistical mechanics

Popular dissertations yesterday (2023-09-27)

• The science of imagining solutions : design becoming conscious of itself through design
• Interfacial Properties of Biomacromolecular Model Systems: Surface Forces and Nanotribology
• Analysis of Genes and Proteins Involved in Wood Formation
• Dynamic Optimization of Transportation Networks with Delays
• Well, that makes sense! : Investigating opportunity development in a technology start-up
• Assessment of shear and energy?absorption capacity of reinforced concrete elements under impulsive loads
• Digital Work : Coping with Contradictions in Changing Healthcare
• Wear of spur and helical gears
• Modeling glioblastoma heterogeneity to decipher its biology
• Dynamic Software Architectures
• Popular complementary terms: essays, phd thesis, master thesis, papers, importance, trend, impact, advantages, disadvantages, role of, example, case study.

See yesterday's most popular searches here . Dissertations.se is the english language version of Avhandlingar.se .